Alexandra Forestier
Alexandra Forestier is an expert in Internal medicine at Centre Oscar Lambret (France). Alexandra Forestier has authored 34 publications, the most recent in 2026, and is an investigator in 2 clinical trials, 1 of them ongoing. SLR score: 144 (community average: 125). How the SLR is computed.
LeadR Profile
Internal medicine
Subspecialties: Oncology - Rheumatology - Critical Care
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 34
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Efficacy and safety of immune checkpoint inhibitor rechallenge in cervical and endometrial cancer: a multi-center retrospective study (RICE study). PMID 42538280 — cells, confidence intervals, safety, progression-free survival, retrospective studies, neoplasms, multiple chronic conditions, drug therapy, drug-related side effects and adverse reactions, immune checkpoint inhibitors, apoptosis regulatory proteins, therapeutics, programmed cell death 1 receptor, cell death, endometrial neoplasms, chemotherapy | Int J Gynecol Cancer | 2026 | 1 |
| Fat mass and survival in immunotherapy-treated metastatic renal cell carcinoma patients. PMID 42461914 — cells, muscles, neoplasms, carcinoma, renal cell, biomarkers, immunotherapy, therapeutics | Oncology | 2026 | 0 |
| Life-threatening immune-related adverse events in the intensive care unit: a narrative review. PMID 41123622 — neoplasms, critical care, drug-related side effects and adverse reactions, diagnosis, therapeutics, intensive care units, immunosuppression therapy | Intensive Care Med | 2025 | 1 |
| Immune checkpoint inhibitors-induced large vessel vasculitis: clinical characteristics and management from a European multicentre study. PMID 40139729 — vasculitis, neoplasms, rheumatic diseases, immunotherapy, immune checkpoint inhibitors, diagnosis, therapeutics | Rheumatology (Oxford) | 2025 | 0 |
| [Evaluation of our management circuit for immune-related adverse events in patients with non-metastatic triple-negative breast cancer]. PMID 40483217 — triple negative breast neoplasms, breast neoplasms, neoplasms, drug-related side effects and adverse reactions, breast | Bull Cancer | 2025 | 0 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Prospective Cohort With Clinic biologic Database of Patients Treated by Immunotherapy NCT05223608 — blood, urine specimen collection, neoplasms, immunotherapy | N/A | Recruiting | 2022 |
LeadR Networks
Main global connection map